Evidence map›Paper›PMID 31461379›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.

Joshua W D Tobin, Colm Keane, Jay Gunawardana, Peter Mollee, Simone Birch, Thanh Hoang, Justina Lee, Li Li, Li Huang, Valentine Murigneux and 14 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 4 countries.

Joshua W D TobinMater Research, University of Queensland, Brisbane, QLD, Australia.
Colm KeaneMater Research, University of Queensland, Brisbane, QLD, Australia.
Jay GunawardanaMater Research, University of Queensland, Brisbane, QLD, Australia.
Peter MolleePrincess Alexandra Hospital, Brisbane, QLD, Australia.
Simone BirchPrincess Alexandra Hospital, Brisbane, QLD, Australia.
Thanh HoangDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
Justina LeeDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
Li LiOchsner Health System, New Orleans, LA.
Li HuangOchsner Health System, New Orleans, LA.
Valentine MurigneuxDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
J Lynn FinkDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
Nicholas MatigianDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
Frank VariQueensland Institute of Medical Research, Brisbane, QLD, Australia.
Santiyagu FrancisDiamantina Institute, University of Queensland, Brisbane, QLD, Australia.
Robert KridelPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Oliver WeigertLaboratory for Experimental Leukemia and Lymphoma Research, Munich, Germany.
Sarah HaebeLaboratory for Experimental Leukemia and Lymphoma Research, Munich, Germany.
Vindi JurinovicLaboratory for Experimental Leukemia and Lymphoma Research, Munich, Germany.
Wolfram KlapperUniversity Hospital Schleswig-Holstein, Kiel, Germany.
Christian SteidlBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Laurie H SehnBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Soi-Cheng LawMater Research, University of Queensland, Brisbane, QLD, Australia.
Michelle N WykesQueensland Institute of Medical Research, Brisbane, QLD, Australia.
Maher K GandhiMater Research, University of Queensland, Brisbane, QLD, Australia.
The University of Queensland · AUGerman Cancer Research Center · DEPrincess Alexandra Hospital · AUBC Cancer Agency · CAMater Research · AUOchsner Health System · USQIMR Berghofer Medical Research Institute · AUPrincess Margaret Cancer Centre · CAUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUnderstanding the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) remains a priority. Solid tumors with low levels of intratumoral immune infiltration have inferior outcomes. It is unknown whether a similar relationship exists between POD24 in FL. PATIENTS AND

methodsDigital gene expression using a custom code set-five immune effector, six immune checkpoint, one macrophage molecules-was applied to a discovery cohort of patients with early- and advanced-stage FL (n = 132). T-cell receptor repertoire analysis, flow cytometry, multispectral immunofluorescence, and next-generation sequencing were performed. The immune infiltration profile was validated in two independent cohorts of patients with advanced-stage FL requiring systemic treatment (n = 138, rituximab plus cyclophosphamide, vincristine, prednisone; n = 45, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), with the latter selected to permit comparison of patients experiencing a POD24 event with those having no progression at 5 years or more.

resultsImmune molecules showed distinct clustering, characterized by either high or low expression regardless of categorization as an immune effector, immune checkpoint, or macrophage molecule. Low programmed death-ligand 2 (PD-L2) was the most sensitive/specific marker to segregate patients with adverse outcomes; therefore, PD-L2 expression was chosen to distinguish immune infiltration

conclusionAssessment of immune-infiltration by PD-L2 expression is a promising tool with which to help identify patients who are at risk for POD24.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDatabases, FactualDisease ProgressionGermanyHumansLymphocytes, Tumor-InfiltratingLymphoma, FollicularNorth AmericaProgrammed Cell Death 1 Ligand 2 ProteinProgression-Free SurvivalQueenslandRisk FactorsTime FactorsTranscriptomeBiomarkers, TumorPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 Protein

Identifiers

PMID31461379
PMCPMC6881104
OpenAlexW2970789858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.